Moderna (MRNA)
(Delayed Data from NSDQ)
$86.84 USD
+0.22 (0.25%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $86.91 +0.07 (0.08%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$86.84 USD
+0.22 (0.25%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $86.91 +0.07 (0.08%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth D Momentum D VGM
Zacks News
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Thermo Fisher (TMO) Extends Collaboration With Symphogen
by Zacks Equity Research
Thermo Fisher's (TMO) recent extension of collaboration with Symphogen is intended to support biopharmaceutical discovery and development.
The Zacks Analyst Blog Highlights Moderna, Gilead Sciences, Kodiak Sciences and Lexicon Pharmaceuticals
by Zacks Equity Research
Moderna, Gilead Sciences, Kodiak Sciences and Lexicon Pharmaceuticals have been highlighted in this Analyst Blog.
Biotech Stock Roundup: MRNA's Q4 Earnings, LXRX, KOD Down on Updates & More
by Zacks Equity Research
Updates from Moderna (MRNA) and Kodiak Sciences Inc (KOD) are a few key highlights from the biotech sector during the past week.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Novavax's (NVAX) Q4 Loss Wider Than Expected, 2022 View Weak
by Zacks Equity Research
Novavax (NVAX) reports a wider-than-expected loss for the fourth quarter of 2021. Also, revenues miss estimates. Its shares decline in after-market trading following the announcement.
Thermo Fisher (TMO) Extends Collaboration With Moderna
by Zacks Equity Research
Thermo Fisher (TMO) continues to be a trusted partner of Moderna, bringing a wide range of products and services enabling Moderna to deliver innovative medicines at an extraordinary speed and scale.
Moderna (MRNA) Just Reclaimed the 20-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
Moderna (MRNA) Q4 Earnings Top, COVID-19 Vaccine Brings $7B
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine sales beat expectations. The company delivers 297 million doses of its COVID-19 vaccine during the fourth quarter. Stock gains in pre-market.
Moderna (MRNA) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of 14.85% and 7.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
5 Intriguing Earnings Charts
by Tracey Ryniec
Will these 5 companies break out, or break down, after they report earnings this week?
Drug/Biotech Stocks' Q4 Earnings on Feb 24: MRNA, EBS & More
by Zacks Equity Research
Let us take a look at five biotech/drug companies, namely, MRNA, EDIT, VIR, EBS and AERI, which are due to release their quarterly results on Feb 24.
Endo (ENDP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Endo's (ENDP) fourth-quarter earnings might have gained from higher sales of Xiaflex.
Geopolitical Fear From Russia's Ukrainian-Advance Drive Stocks Lower
by Daniel Laboe
The US's economic growth outlook, inflationary issues, and uncertain monetary policy are far more important than anything happening in Eastern Europe when assessing the stock market from a macro perspective
What to Expect From Precision BioSciences (DTIL) Q4 Earnings
by Zacks Equity Research
On Precision BioSciences' (DTIL) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline.
Universal Health (UHS) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Universal Health Services' (UHS) fourth-quarter results are likely to reflect the benefits of improving patient volumes.
Is a Beat Likely for Moderna (MRNA) This Earnings Season?
by Zacks Equity Research
Investor focus is likely to be on the progress of Moderna's (MRNA) late-stage pipeline candidates on the fourth-quarter earnings call that reduce its dependence on Spikevax.
Allakos (ALLK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Allakos' (ALLK) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's lead pipeline candidate, lirentelimab.
Moderna (MRNA) Stock Moves -0.42%: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $145.74 in the latest trading session, marking a -0.42% move from the prior day.
Moderna (MRNA) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Moderna (MRNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BridgeBio (BBIO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On BridgeBio Pharma's (BBIO) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline candidates.
Mednax (MD) to Post Q4 Earnings: Here's What You Need to Know
by Zacks Equity Research
Mednax's (MD) fourth-quarter results are likely to reflect growth in same-unit revenues and NICU days.
Stock Market News for Feb 15, 2022
by Zacks Equity Research
Wall Street lower on Monday as geopolitical tensions between Russia and Ukraine intensified.
Will Patient Days Drive Community Health (CYH) Q4 Earnings?
by Zacks Equity Research
Community Health Systems' (CYH) fourth-quarter results are likely to reflect a higher occupancy rate and average length of stay.
Pfizer (PFE) Plans to Delay Comirnaty for Kids EUA Submission
by Zacks Equity Research
Pfizer (PFE) and its partner BioNTech are planning to extend their rolling submission to the FDA for the authorization of Comirnaty for use in children 6 months through 4 years of age to include the three-dose data.